PolyProx Therapeutics is developing biopharmaceuticals, called Polyproxin™ molecules, that target and remove disease-causing proteins using the natural degradation machineries contained within the cell.
Our initial focus is in developing Polyproxin™ drug candidates for use in the treatment of cancers, targeting aberrant proteins that have previously proven difficult to target using conventional drug classes, such as small molecules or monoclonal antibodies.
Polyproxin™ molecules were discovered during over a decade of research in the field of protein structure, folding and stability at the laboratory of founder Professor Laura Itzhaki, Department of Pharmacology, University of Cambridge UK. Working with co-founders Dr Pamela Rowling and Dr Albert Perez-Riba, they discovered that a novel class of designed proteins can be repurposed to direct disease-causing targets for destruction.
Our initial focus is in developing Polyproxin™ drug candidates for use in the treatment of cancers.
The Company was formed in 2018 based on these inventions, which are protected by a strong intellectual property portfolio that has been exclusively licensed from Cambridge Enterprise. Professor Itzhaki serves as Chief Scientific Officer, working with serial entrepreneurs Andrew Sandham, Executive Chairman, and Dr Kevin Moulder, Chief Operating Officer. Our laboratories are located at the prestigious Babraham Research Campus, Cambridge UK.